Holen Sie sich die Stockscreener-App
1.29
1.53%
-0.02
Handel nachbörslich:
1.31
0.02
+1.55%
Milestone Pharmaceuticals Inc Aktie (MIST) Neueste Nachrichten
Milestone Pharmaceuticals (MIST) investors approve equity plan, elect board and ratify PwC - Stock Titan
Milestone (NASDAQ: MIST) director receives 77,000 stock options grant - Stock Titan
Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 strike - Stock Titan
Milestone Pharmaceuticals (MIST) awards director 77,000 stock options - Stock Titan
Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 - Stock Titan
Director at Milestone Pharmaceuticals (MIST) receives 77,000 stock options at $1.22 - Stock Titan
Milestone Pharmaceuticals (NASDAQ: MIST) director receives 77,000 stock options grant - Stock Titan
Milestone Pharmaceuticals (MIST) director receives grant of 77,000 stock options - Stock Titan
Milestone Pharmaceuticals: Here Comes The Revenue Ramp (NASDAQ:MIST) - Seeking Alpha
Novartis Canada and the pan-Canadian Pharmaceutical Alliance Achieve Milestone Agreement Enabling Public Reimbursement of (pr)Scemblix® (asciminib tablets) - Newswire Canada
Milestone Pharmaceuticals: Taking The Long View (NASDAQ:MIST) - Seeking Alpha
Eli Lilly scores a first in major pharma milestone - thestreet.com
Heart Rhythm Society and Milestone Pharmaceuticals Partner to Expand SVT Patient Education Through UpBeat.org - PR Newswire
Wockhardt's Zaynich wins US FDA approval, marking milestone in antibiotic innovation - Business Today
Milestone (MIST) Q1 2026 Earnings Transcript - The Globe and Mail
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - PR Newswire
Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST) - The Globe and Mail
[EFFECT] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
Milestone Pharmaceuticals (MIST) Slides 7.24% as Selling Pressure Builds—Key Support at $1.34 in FocusOBV Divergence - thelegaladvocate.com
Milestone Pharmaceuticals Q1 earnings call highlights - MSN
MIST Stock Price, Quote & Chart | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment - Investing.com
Milestone reports Q1 results, highlights initial CARDAMYST sales - MSN
MIST Technical Analysis | Trend, Signals & Chart Patterns | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Milestone Pharmaceuticals Q1 2026 earnings preview - MSN
Milestone outlines ~2-year phase III AFib-RVR timeline as CARDAMYST launch reaches ~600 prescriptions - MSN
Milestone Pharmaceuticals (MIST) reports Q1 loss, lags revenue estimates - MSN
RTW Investments (MIST) and Roderick Wong disclose 9.99% ownership - Stock Titan
Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Path To Profitability - Yahoo Finance
Milestone Pharmaceuticals Inc. (NASDAQ:MIST): Is Breakeven Near? - simplywall.st
Milestone Pharmaceuticals (MIST) Gets a Buy from Piper Sandler - The Globe and Mail
MIST Maintained by Wells Fargo -- Price Target Lowered to $7.00 - GuruFocus
Milestone Pharmaceuticals Is Maintained at Overweight by Wells Fargo - Moomoo
Wells Fargo & Company Issues Pessimistic Forecast for Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price - MarketBeat
Milestone Pharmaceuticals Inc.Common Shares (NQ: MIST - FinancialContent
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - The Manila Times
NASDAQ fireside chat: Milestone talks cardiovascular drugs on May 19 - Stock Titan
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Q1 2026 Earnings Call Transcript - Insider Monkey
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Raises Target Price to $7 - Moomoo
Milestone Pharmaceuticals Inc. Q1 2026 10-Q Report: Financial Statements, Risk Factors, and Forward-Looking Statements – Minichart - Minichart
TD Cowen Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Milestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highl - GuruFocus
Milestone Pharmaceuticals Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Milestone Pharmaceuticals Files $300 Million Mixed Shelf - Moomoo
Why Milestone Pharmaceuticals stock wilted on Wednesday - MSN
Why Milestone Pharmaceuticals Stock Wilted on Wednesday - The Motley Fool
Milestone Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $6.33, Implies 233% Upside - TradingView
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Milestone Pharmaceuticals Inc. may issue and sell common shares worth up to 100 million dollars through an equity distribution sales agreement with Cantor Fitzgeral - Bitget
Milestone Pharmaceuticals IncMay offer securities up to $300 millionSEC filing - marketscreener.com
Milestone Pharmaceuticals (NASDAQ: MIST) files $300M shelf; $100M ATM with Cantor Fitzgerald - Stock Titan
Q1 2026 Milestone Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
H.C. Wainwright Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Milestone Pharmaceuticals (NASDAQ:MIST) Issues Earnings Results - MarketBeat
Milestone Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Milestone Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Milestone Pharmaceuticals (MIST) Reports Q1 Earnings Miss - GuruFocus
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):